Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015

Timothy Price; Subotheni Thavaneswaran; Matthew Burge; Eva Segelov; Daniel Haller; Cornelis Punt; Dirk Arnold; Christos Karapetis; Niall Tebbutt; Nick Pavlakis; Peter Gibbs; Jeremy Shapiro

doi:10.1586/14737140.2016.1170594

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015

Timothy Price, Subotheni Thavaneswaran, Matthew Burge, Eva Segelov, Daniel Haller, Cornelis Punt, Dirk Arnold, Christos Karapetis, Niall Tebbutt, Nick Pavlakis, Peter Gibbs, Jeremy Shapiro

Research output: Contribution to journal › Review article › peer-review

6 Citations (Scopus)

Abstract

ABSTRACT: The treatment of metastatic CRC (mCRC) has evolved over the last 20 years, from fluoropyrimidines alone to combination chemotherapy and new biologic agents. Median overall survival is now over 24 months for RAS mutated (MT) patients and over 30 months for RAS wild-type (WT) patients. However, there are subgroups of patients with BRAF V600E MT CRC who have a significantly poorer outlook. Newer treatment options are also being explored in select subgroups of patients (anti-HER 2 in HER2 positive mCRC and immunotherapy in patients with defective mismatch repair (dMMR)). The best use of these systemic treatment options, as well as surgery in well-selected patients requires careful consideration of predictive biomarkers and importantly, the optimal sequence in which therapies should be given to derive maximal benefit. A group of colorectal subspecialty medical oncologists from Australia, USA, The Netherlands and Germany met during ECCO 2015 in Vienna to review current practice.

Original language	English
Pages (from-to)	557-571
Number of pages	15
Journal	Expert Review of Anticancer Therapy
Volume	16
Issue number	5
DOIs	https://doi.org/10.1586/14737140.2016.1170594
Publication status	Published - 3 May 2016

Keywords

biological
chemotherapy
Colorectal cancer
Consensus
RAS
VEGF

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/14737140.2016.1170594

Cite this

@article{3e8c7db3e3ae4aa9ac3d8def4b6c4704,

title = "Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015",

abstract = "ABSTRACT: The treatment of metastatic CRC (mCRC) has evolved over the last 20 years, from fluoropyrimidines alone to combination chemotherapy and new biologic agents. Median overall survival is now over 24 months for RAS mutated (MT) patients and over 30 months for RAS wild-type (WT) patients. However, there are subgroups of patients with BRAF V600E MT CRC who have a significantly poorer outlook. Newer treatment options are also being explored in select subgroups of patients (anti-HER 2 in HER2 positive mCRC and immunotherapy in patients with defective mismatch repair (dMMR)). The best use of these systemic treatment options, as well as surgery in well-selected patients requires careful consideration of predictive biomarkers and importantly, the optimal sequence in which therapies should be given to derive maximal benefit. A group of colorectal subspecialty medical oncologists from Australia, USA, The Netherlands and Germany met during ECCO 2015 in Vienna to review current practice.",

keywords = "biological, chemotherapy, Colorectal cancer, Consensus, RAS, VEGF",

author = "Timothy Price and Subotheni Thavaneswaran and Matthew Burge and Eva Segelov and Daniel Haller and Cornelis Punt and Dirk Arnold and Christos Karapetis and Niall Tebbutt and Nick Pavlakis and Peter Gibbs and Jeremy Shapiro",

year = "2016",

month = may,

day = "3",

doi = "10.1586/14737140.2016.1170594",

language = "English",

volume = "16",

pages = "557--571",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Taylor & Francis",

number = "5",

}

TY - JOUR

T1 - Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015

AU - Price, Timothy

AU - Thavaneswaran, Subotheni

AU - Burge, Matthew

AU - Segelov, Eva

AU - Haller, Daniel

AU - Punt, Cornelis

AU - Arnold, Dirk

AU - Karapetis, Christos

AU - Tebbutt, Niall

AU - Pavlakis, Nick

AU - Gibbs, Peter

AU - Shapiro, Jeremy

PY - 2016/5/3

Y1 - 2016/5/3

N2 - ABSTRACT: The treatment of metastatic CRC (mCRC) has evolved over the last 20 years, from fluoropyrimidines alone to combination chemotherapy and new biologic agents. Median overall survival is now over 24 months for RAS mutated (MT) patients and over 30 months for RAS wild-type (WT) patients. However, there are subgroups of patients with BRAF V600E MT CRC who have a significantly poorer outlook. Newer treatment options are also being explored in select subgroups of patients (anti-HER 2 in HER2 positive mCRC and immunotherapy in patients with defective mismatch repair (dMMR)). The best use of these systemic treatment options, as well as surgery in well-selected patients requires careful consideration of predictive biomarkers and importantly, the optimal sequence in which therapies should be given to derive maximal benefit. A group of colorectal subspecialty medical oncologists from Australia, USA, The Netherlands and Germany met during ECCO 2015 in Vienna to review current practice.

AB - ABSTRACT: The treatment of metastatic CRC (mCRC) has evolved over the last 20 years, from fluoropyrimidines alone to combination chemotherapy and new biologic agents. Median overall survival is now over 24 months for RAS mutated (MT) patients and over 30 months for RAS wild-type (WT) patients. However, there are subgroups of patients with BRAF V600E MT CRC who have a significantly poorer outlook. Newer treatment options are also being explored in select subgroups of patients (anti-HER 2 in HER2 positive mCRC and immunotherapy in patients with defective mismatch repair (dMMR)). The best use of these systemic treatment options, as well as surgery in well-selected patients requires careful consideration of predictive biomarkers and importantly, the optimal sequence in which therapies should be given to derive maximal benefit. A group of colorectal subspecialty medical oncologists from Australia, USA, The Netherlands and Germany met during ECCO 2015 in Vienna to review current practice.

KW - biological

KW - chemotherapy

KW - Colorectal cancer

KW - Consensus

KW - RAS

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84973641563&partnerID=8YFLogxK

U2 - 10.1586/14737140.2016.1170594

DO - 10.1586/14737140.2016.1170594

M3 - Review article

SN - 1473-7140

VL - 16

SP - 557

EP - 571

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 5

ER -

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this